New Treatment Approved for ALK-positive NSCLC

Juhi Kunde, Director of Science and Research Marketing
new treatment alk lung cancer

On November 17, 2026, the US Food and Drug Administration (FDA) announced the accelerated approval of neladalkib (Nelkarmi) to treat patients with locally-advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC).  

This approval is for patients who have been previously treated with ALK tyrosine kinase inhibitors (TKIs).

Fusions in the ALK gene, where ALK is joined with another protein, such as EML4, are responsible for approximately 5% of NSCLCs in Western populations. This type of lung cancer is more common in younger patients (median age is 52 years) and people with light smoking history or those with no tobacco exposure.

Patients have experienced significant benefits from ALK-targeted therapies, such as alectinib. However, the tumors eventually develop resistance to treatment which allows them to begin growing again.

Neladalkib is a type of targeted therapy that is given as a daily pill.  It is a tyrosine kinase inhibitor (TKI) that is designed to overcome drug resistance in ALK-positive NSCLC.

This FDA approval is supported by data from the ALKOVE-1 clinical trial that was conducted internationally. The trial studied 67 patients who were previously treated with alectinib and 155 patients who received two or more TKIs plus chemotherapy.  

For the patients previously treated with alectinib, the study showed 49% of patients had their tumors shrink or disappear with neladalkib treatment (overall response rate). In addition, 52% of patients responded to treatment for 12 months or longer (duration of response).

For patients who were previously treated with two or more TKIs plus chemotherapy, the data showed 32% of patients had their tumors shrink or disappear with neladalkib treatment (overall response rate). In addition, 51% of patients responded to treatment for 12 months or longer (duration of response).

For more information, please see the FDA’s press release.